Treatment of patients with idiopathic pulmonary fibrosis in real-life setting: Results from the Latin American Pulmonary Fibrosis Registry REFIPI

Le résumé fourni par la source

Treatment of patients with IPF in real-life clinical setting: Results from the Latin American Pulmonary Fibrosis Registry (REFIPI) Introduction: Until now, we didn´t have data about anti-fibrotic management of patients with idiopathic pulmonary fibrosis (IPF) in Latin America. The REFIPI is the first IPF registry across Latin America. Objectives: To define the characteristics of patients with antifibrotic treatment and compare adverse effects (AE) between pirfenidone and nintedanib. Methods: Multicentric retrospective cohort study. Patients were included retrospectively from Nov 2017 to Nov 2018. Cases were reported via a web-based platform and approval was confirmed by a central multidisciplinary diagnostic team according to 2011 IPF official statement. Results: 433 patients from 11 countries were enrolled. 64% received anti-fibrotics: 14% nintedanib, 78% pirfenidone and 8% both at different times. AEs were reported in 33% patients with pirfenidone (nausea 26%, photosensitivity 10% and diarrhea 3%) and 51% with nintedanib (nausea 5%, diarrhea 49%). Discontinuation occurred in 9% with pirfenidone vs 18% with nintedanib (p=0.086). Antifibrotics were more frequent in countries with ILD reference centers: 68% vs 48%, p<0.01. The use of Pirfenidone was more frequent in patients > 70 years (65% vs 45%, p=0.014) and with FVC <50% (15% vs 5%, p=0.09) Conclusion: We found similar profile but lower frequency of AEs and lower rate of discontinuation than in the clinical trials. Pirfenidone was more frequently used maybe by accesibility. REFIPI provides unique regional information about IPF treatment in real-world clinical setting.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.